key: cord-0815417-9crhn87h
authors: Kumar, Raman; Himani; Haq, Afrozul; Wimalawansa, Sunil J.; Sharma, Alpana
title: Putative Roles of Vitamin D in Modulating Immune Response and Immunopathology Associated With COVID-19
date: 2020-11-21
journal: Virus Res
DOI: 10.1016/j.virusres.2020.198235
sha: 6c339fc119ab5c8adaf485684a91fc5e6fad856c
doc_id: 815417
cord_uid: 9crhn87h

The first incidence of COVID-19 was reported in the Wuhan city of Hubei province in China in late December 2019. Because of failure in timely closing of borders of the affected region, COVID-19 spread across like a wildfire through air travel initiating a pandemic. It is a serious lower respiratory track viral infection caused by highly contagious, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Coronavirus including COVID-19 causing SARS-CoV-2 causes zoonotic diseases and thought to be originated from bats. Since its first incidence, the virus has spread all across the world, causing serious human casualties, economic losses, and disrupting global supply chains. As with SARS-CoV, COVID-19 causing SARS-CoV-2 follows a similar path of airborne infection, but is less lethal and more infectious than SARS and MERS. This review focusses on the pathogenesis of SARS-CoV-2, especially on the dysfunctional immune responses following a cytokine storm in severely affected persons. The mode of entry of SARS-CoV-2 is via the angiotensin converting enzyme 2 (ACE-2) receptors present on the epithelial lining of lungs, gastrointestinal tract, and mucus membranes. Older persons with weaker immune system and associated co-morbidities are more vulnerable to have dysfunctional immune responses, as most of them concomitantly have severe hypovitaminosis D. Consequently, causing severe damage to key organs of the body including lungs and the cardiovascular system. Since, vast majority of persons enters to the intensive care units and died, had severe vitamin D deficiency, thus, this area must be investigated seriously. In addition, this article assesses the role of vitamin D in reducing the risk of COVID-19. Vitamin D is a key regulator of the renin-angiotensin system that is exploited by SARS-CoV-2 for entry into the host cells. Further, vitamin D modulates multiple mechanisms of the immune system to contain the virus that includes dampening the entry and replication of SARS-CoV-2, reduces concentration of pro-inflammatory cytokines and increases levels of anti-inflammatory cytokines, enhances the production of natural antimicrobial peptide and activates defensive cells such as macrophages that could destroy SARS-CoV-2. Thus, this article provides the urgency of needed evidences through large population based randomized controlled trials and ecological studies to evaluate the potential role of vitamin D in COVID-19.

We are amidst a socioeconomic and health catastrophic global pandemic, which brought the global economic collapse, that worsens by prolonged lockdowns and curfews.

The latter two has little effects on controlling the disease but has major impact on destructing the likelihoods of millions of people and the economies of all affected countries.

In December 2019, reports came about a cluster of patients suffering from severe acute respiratory syndrome linked to seafood and wet animal market in the Wuhan city, Hubei province of China [1] , but later found that the said location was incorrect. World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020 and the disease causing virus was classified as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) on same day by International Committee on Taxonomy of Viruses (ICTV) [2] . Previously, two major epidemics of coronavirus, the severe acute respiratory syndrome (SARS)-CoV [3] and middle east respiratory syndrome (MERS)-CoV [4] , both originated from wild animals and were transmitted to humans. Major cause of death was reported as severe atypical pneumonia [5, 6] . SARS-CoV-2 enters the human body by attaching to its cognate angiotensin converting enzyme-2 (ACE-2) receptor; located on the epithelium lining of lungs and other organs via its spike protein [1] . Once internalized, viral RNA strands replicate uninterruptedly using the host's polymerase system and further invades other host cells causing severe pathological changes, including cell death. The virus also evade the host's immune system through multiple mechanisms including excessive stimulation of renin-angiotensin system (RAS) [7] . SARS-CoV-2 seems to hijack and modulate the RAS system, not only initiating an excess generation of angiotensin-II fuelling the cytokine storm but also down regulating host's immune system thus favouring the propagation of the virus.

In some COVID-19 cases, manifestation of dysfunctional immune responses include, J o u r n a l P r e -p r o o f triggering a cytokine storm involving increased secretion of pro-inflammatory cytokines in circulation which leads to acute respiratory distress syndrome (ARDS) and ultimately death.

Vitamin D regulates the immune modulatory mechanisms by decreasing proinflammatory environment in-vivo, and increases secretion of anti-inflammatory cytokines. It has been reported that 25(OH)D deficiency, a physiologically quantifiable form of vitamin D, is strongly associated with unfavourable clinical outcome. Lastly, no adverse effects of using high doses of vitamin D in COVID-19 and other circumstances has been reported.

In addition to above, immune suppressor role of dexamethasone, a potent corticosteroid, has also been discussed in preventing the need of ventilator support in severely and critically ill COVID-19 patients. Thus, this review addresses pathogenesis of SARS-CoV-2 and mechanisms opted for immune evasion along with plausible role of vitamin D in regulating these immune evasion mechanisms for the successful eradication of pathogen from the host.

Coronavirus (CoVs) are enveloped, positive single-stranded RNA virus having ability to infect both humans and animals. Under electron microscope, they look like spherical entities along with core shell and have glycoprotein projections on their envelop, which gives them appearance like crown, hence named as coronavirus (figure 1) [8] . In 1966, Tyrell and Bynoe for the first-time identified coronavirus (CoVs) in patients suffering from acute upper respiratory illnesses [8] . Most coronavirus (CoVs) cause infections limiting to upper respiratory tract, while some CoVs such as beta-CoVs subgroup, including SARS-CoV, SARS-CoV-2 (COVID- 19) , and MERS-CoV cause lower respiratory tract infections resulting in severe complications and higher mortality. By 14 th November 2020, the total confirmed COVID-19 cases were 53,164,803 and 1,300,576 deaths with a case fatality rate of and MERS-CoV infected cases [14, 15, 20, 21] . In COVID-19 patients, ARDS develops due to difficulty in breathing and low blood oxygen levels which ultimately leads to respiratory failure as observed in 70 % of severe COVID-19 cases [22] . Further, a spurt of cytokines release in response to viral infection results in cytokine storm and sepsis leading to 28 % deaths in critical COVID-19 cases [22] . Multiple organs failure are also observed in some patients due to uncontrolled inflammation caused by these pro-inflammatory cytokines [23, 24] .

Initially, SARS-CoV-2 attaches with angiotensin converting enzyme (ACE2) receptor which is present on majority of lung cells including epithelial cells, alveolar epithelial cells, vascular endothelial cells and macrophages and then enters via endocytosis [25, 26] . The SARS-CoV-2 mode of entry is similar to SARS-CoV, thus it is likely that SARS-CoV-2 uses the similar cell subsets and related pathogenesis [27] . SARS-CoV reduces the expression of ACE2 receptor which in turn is associated with acute lung injury and thus disease pathology. ACE2 regulates RAS, thus its downregulation will disrupt RAS homeostasis and ultimately affecting blood pressure, electrolyte balance, increasing inflammation and vascular permeability in the airways [7] . Coronavirus attaches to the receptor of host cell through spike glycoprotein (S), and once inside the cell this spike protein divides into S1 and S2 subunits. S1 regulates virus-host range and cellular tropism with the receptor binding domain (RBD) [28, 29] , whereas S2 helps in virus cell membrane fusion with the help of two tandem domains, heptad repeats 1 and 2 (HR1 & HR2) [30, 31] . After the fusion, it releases viral RNA genome into cytoplasm thus initiating replication and transcription of virus in host cell cytoplasm. Positive RNA genome acts as a messenger RNA (mRNA) and is translated into pp1a and pp1ab, two large precursor polyproteins and these polyproteins in the presence of ORF 1a-encoded viral proteinases, 3C-like proteinases (3CLpro) and papain-like proteinase (PLpro) gets processed into 16 mature non-structural J o u r n a l P r e -p r o o f proteins (nsp1-nsp16) [32, 33] . During viral RNA replication and transcription these nonstructural proteins (nsps) perform vital functions. Despite sharing of only 79 % genome sequence identity of SARS-CoV-2 with SARS-CoV, it displays high infectivity rate which could be due to the presence of furin-like cleavage site in S protein which is absent in SARS-CoV [34] .

Cytopathic virus including SARS-CoV-2 during virus replicative cycle causes tremendous destruction of infected cells and tissues thus triggering a local immune response due to virus linked pyroptosis and recruiting macrophages and monocytes [35, 36] .

Pyroptosis, a type of programmed cell death leads to extensive inflammation and secretion of IL-1β, a crucial inflammatory molecule [15, 37] . Alveolar macrophage detects the pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) present on the virus particle using pattern recognition receptors (PRRs) and generates local inflammation and releasing a spurt of cytokines and chemokines including IL-6, IFN-γ, MCP1 and IP-10 in the circulation of COVID-19 cases [15, 22] . Their secretion attracts various immune cells at affected organ including monocytes and T-lymphocytes thus conforming the lymphopenic situation along with increased neutrophil-lymphocyte ratio as observed in 80 % of the COVID-19 cases [14, 38] .

In majority of COVID-19 patients, these recruited cells eradicate the infection leading to patient's recovery, but in some severe cases, a defective immune response arises, which activates a cytokine storm causing extensive lung inflammation. Severe COVID-19 patients have elevated levels of IL-2, IL-7, MCP1, G-CSF, IP-10, IL-10, MIP1α and TNF [15] .

Literature reported that IL-6 levels were considerably higher in non-survivors compared to survivors [39] . Further, increased percentage of CD14+CD16+ inflammatory monocytes has also been observed in peripheral blood of severe COVID-19 patients than patients with mild infection, thus further triggering of cytokines release (figure 2) [40] .

Though disruptive mechanisms used by SARS-CoV-2 in inhibiting the body's innate antiviral cytokine response are yet to be unveiled, the initial evidences on SARS-CoV revealed that viral structural and non-structural proteins might inhibit the interferon pathway activation through multiple mechanism including prevention of PRRs recognition, inhibition of signalling pathways, host mRNA degradation, and hindering host protein degradation. This antagonism of interferon response promotes viral replication and leads to aberrant inflammatory responses [41, 42] .

This unrestrained infiltration of inflammatory cells causes extensive destruction of lung cells and tissue via protease and reactive oxygen species secretion leading to massive pathological changes in the lung including desquamation of alveolar cells, hyaline membrane formation, pulmonary oedema [43] . These pathological changes decrease efficient gaseous exchanges and low blood oxygen levels. Apart from local damage, the spurt of cytokine levels including TNF-α causes septic shock and leads to multi organ failure [44] . Patients with more than 60 years and those associated with co-morbidities are more susceptible to display dysfunctional immune response. In contrast, children despite having high viral titres do not develop severe disease [45] .

The first autopsy of COVID-19 patient showed mononuclear cells accumulation (probably monocytes and T cells) in lungs, and deficit of hyperactive T cells in peripheral blood [43] . One week after onset of COVID-19 symptoms, both T and B cells against SARS-CoV-2 have been detected in the peripheral blood. CD8+ T cells directly attacks and kills the virus whereas CD4+ cells primed the CD8+ T cells and B cells. Further, CD4+ T cells are involved in immune cells recruitment through cytokines production. SARS-CoV-specific CD4+ T cells displays IFN-γ, TNF, IL-2 chemokines, thereby suggesting Th1 immune response and cell mediated immunity, a reason for extensive immunopathogenesis [46] .

Although several vaccine formulations against SARS-CoV showed signs of immunopathology, still this T cells vaccine holds promising avenues in eliminating the virus, but it must be ascertained whether they alone are capable of preventing infection in human setting or need to be complemented with other conjugates is a matter of further investigation [47, 48] . Similarly, in COVID-19, B cells response is reported to occur after 1-week post onset of symptoms. In SARS-CoV infection, initially response is against nucleocapsid (N) protein, 4-8 days later post symptoms, antibody response against spike (S) protein can also be seen and reaches to its peak by the end of third week. In contrast, viral titre peaks earlier for SARS-CoV-2 than SARS, thus antibody response might also arise earlier [17, 18] .

Antibody response holds great promise as convalescent plasma therapy have demonstrated good clinical results in COVID-19 cases [49] . In China, initial efforts in treating COVID-19 patients with polyclonal antibodies holds great promise in reducing viral titre and mortality [50, 51] . Further, various monoclonal antibodies raised against RBD of S protein working efficiently against SARS-CoV also neutralized SARS-CoV-2 virus, but majority do not, thus underline the importance of dissimilar protein sequence in the RBDs of SARS-CoV-2 and SARS-CoV.

Current management of COVID-19 is supportive, and respiratory failure from ARDS is the leading cause of mortality. Numerous drugs avenues are being explored for the treatment and management of COVID-19. Remdesivir was initially developed for the treatment of Ebola, MERS-CoV, SARS-CoV [52] . It is a potential nucleoside inhibitor that Lopinavir and ritonavir are two protease inhibitors initially designed for anti-retroviral therapy (ART) and showed promising results in SARS [53] . Hydroxychloroquine is an antimalarial drug and it works on the principle of inhibition of viral replication [54] . Further, it also acts as immunosuppressant by reducing IL-6 and TNF-α levels. The drug interferes with the ACE2 receptor glycosylation and ultimately blocks the viral entry into the host cells. Vitamin D deficiency is an important factor in the mitigation of the amplified and persistent inflammation, a cardinal feature of ARDS [79] [80] [81] . In various diseases including influenza, respiratory syncytial virus infection (RSV), and tuberculosis, vitamin D deficiency has been a consistent factor [82, 83] . A significant association has been observed between vitamin D deficiency and seasonal diseases like influenza during the winter periods [84] . was also associated with lower risk of unconsciousness and hypoxia. In addition to that, only 9.7% patients succumbed to death who were vitamin D sufficient whereas mortality percentage was upto 20% in those who had serum 25(OH)D levels <30 ng/ml. Thus, decreased levels of CRP and increased percentage lymphocyte in circulation indicates that vitamin D sufficiency might play important role in modulating the immune response of the infected patients [88] .

Vitamin D has been reported to mitigate the symptoms of common cold and influenza [89] . Further, it augments cell mediated immunity, regulates adaptive immunity, and increases expression of genes associated with antioxidants [90] [91] [92] . It has been reported that nearly 40% of the Europeans are deficient in the vitamin D, irrespective of their age, sex, skin textures and latitudes [93] . Similarly, it has been seen that European countries (France; 27.3%, Portugal; 21.2% and Austria; 19.3%) that were severely deficient in vitamin D exhibited significant cases of COVID-19 [94] [95] [96] . Further, countries (e.g. Norway, Finland, Sweden, Denmark and Netherlands; except for the United Kingdom; 23.7%) lacking severely deficient vitamin D did not show COVID-19 cases, thus substantiating its role in COVID-19 management [97] .

Furthermore, few studies have highlighted that high doses of vitamin D may be given to COVID-19 patients especially with confirmed deficiency and also associated with comorbidities such as obese, elder, dark skin texture and those living in higher latitudes [98] .

Additionally, due to its importance in protective effects in several diseases such as cardiovascular disease, diabetes, cancer, respiratory infections and hypertension, experts J o u r n a l P r e -p r o o f suggested that its supplementation and concomitantly increased level of 25(OH)D levels above 50 ng/mL might play important roles in mitigating the incidence and symptom of viral diseases including COVID-19 [99] . Therefore, several authors have emphasized the prophylactic use of vitamin D in the COVID-19 management [24, 100, 101] . Further, in my knowledge, no clinical trial has been made till today to explore the potential of vitamin D in mitigating the effect of SARS-CoV-2 and ultimately COVID-19.

Due to widespread expression of VDR and enzyme CYP27B1 on majority immune cells, vitamin D has got extensive effects on immune cells [102, 103] . The most common is the LL-37, an antimicrobial peptide residing monocytes, B-cells, NK cells, epithelial cells, and γδ T-cells [104, 105] and is also released by respiratory epithelial cells to form a first line of defense against various invading pathogens [106, 107] . Vitamin D in combination with VDR/RXR, binds to the promoter region of cathelicidin, and enhances hCAP-18 production [108] , an innate mechanism to respiratory viruses. Similarly, vitamin D and VDR complex enhances the production of β-defensins which could activate chemotaxis and is shown to prevent RSV infection [109] . In the innate counterpart, vitamin D activates monocyte differentiation into macrophage, activates PI3K signalling pathways for generation of ROS and iNOS oxidative pathway by monocyte and macrophage, an important antiviral mechanism [110] . It also triggers autophagy, which is known to prevent severe immunopathology generally associated with viral infections [111] . Additionally, vitamin D modulates the expression of PRRs including TLR2 and TLR4 in monocytes. This reduction in expression and consequent reduction in PAMPs mediated signalling is required to dampen the excessive inflammation caused due to our innate immune system [102, 112] . [113] . Activation of T cells by DCs is also hampered by reducing expression of costimulatory and MHC class II molecules, resulting in a tolerogenic phenotype. Further, vitamin D treatment also results in decreased production of IL-12 and IL-23 by DCs cells.

Additionally, vitamin D by inhibiting secretion of IL-12 switches the immune axis from Th1 to Th2 phenotype [114] . In addition to that, enhanced production of IL-10 is observed after 

J o u r n a l P r e -p r o o f ARDS features usually develops due to viral replication and hyperactive innate immune response leading to cytokine storm. This spurt of cytokines leads to massive inflammation, disseminated coagulation, shock and hypotension ultimately leading to multi organ failure and death. Since long, dexamethasone, a corticosteroid, has been established as a potent immuno suppressor, that acts by impairing the innate immune response. Further, it has also been seen that patients on long term dexamethasone therapy did not show any features related to severe or critical pneumonia in the presence of COVID-19 [119] .

The major drawback associated with dexamethasone therapy is the continual or exacerbation of viral replication and its progression that might worsen the condition or delay reported that early and low dose of dexamethasone significantly improved the mortality outcome in COVID-19 patients with a sharp reduction in C-reactive protein levels and no escalation in the care related to mechanical ventilation [121] .

Two observational studies showed better clinical outcome in SARS-CoV-2 positive patients [122, 123] . Further Villar et al in a clinical trial over 277 COVID-19 patients reported early removal of ventilation and reduced mortality in patients treated with dexamethasone [124] . In contrary, few studies from China have reported routine usage of dexamethasone but did not show significant benefits to COVID-19 patients [125, 126] . Additionally, one study J o u r n a l P r e -p r o o f reported that dexamethasone stimulated the action of vitamin D levels by upregulating the transcription of VDR gene [127] . Also, dexamethasone decreases the calcitriol induced βcathelicidin levels in human monocytes and bronchial epithelial cell line [128] .

In addition to above, combination of calcitriol and dexamethasone significantly modulates Erk and Akt signaling pathways leading to cell cycle arrest and apoptosis in cancer cells [129] . Thus, it has been demonstrated that dexamethasone holds great promise for severely or critically ill COVID-19 patients but more research or trials are required to set up specific protocols for drug dosage and duration along with combination with other drugs to prevent anti-viral replication and propagation.

In conclusion, this review provides a brief information about the COVID-19 disease and its immune pathogenesis. Initial evidences involved in the mechanism opted by SARS-CoV-2 in the immune evasion were also discussed with few studies. Further, unavailability of potential drugs and their targets warrants intensive research in the repurposing of drugs.

Strong association between vitamin D deficiency and severe viral infections including COVID-19 provided evidences of a simple solution to a complex problem like COVID-19.

Additionally, potential role of vitamin D in modulating the immune response in viral infection further substantiated its importance in the current pandemic situation. In addition to above, potential role of dexamethasone has been highlighted as an anti-inflammatory drug in severe or critically ill COVID-19 patients. Lastly, large scale population based randomized controlled clinical trials are required to unveil the potential of vitamin D alone or in combination with dexamethasone in mitigating the viral infection is required.

Authors declare that they have no conflict of interest. 

A novel coronavirus outbreak of global health concern

Drug firms mobilize to combat coronavirus outbreak

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China

Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

MERS, SARS and other coronaviruses as causes of pneumonia: MERS, SARS and coronaviruses

SARS coronavirus-induced lung injury

Cultivation of a Novel Type of Common-cold Virus in Organ Cultures

World Health Organization. Coronavirus disease (COVID-19) situation reports 114

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The proximal origin of SARS-CoV-2

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical and immunological features of severe and moderate coronavirus disease

Viral load of SARS-CoV-2 in clinical samples

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The trinity of COVID-19: immunity, inflammation and intervention

Clinical characteristics of 82 death cases with COVID-19, Infectious Diseases

Acute renal impairment in coronavirus-associated severe acute respiratory syndrome

GLOBAL EPIDEMIC OF CORONAVIRUS-COVID-19: WHAT CAN WE DO TO MINIMIZE RISKS

ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

The SARS-CoV S glycoprotein: expression and functional characterization

A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2

Severe acute respiratory syndrome coronavirus J o u r n a l P r e -p r o o f (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

Virus-encoded proteinases and proteolytic processing in the Nidovirales

The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Virus Isolation from the First Patient with SARS-CoV-2 in Korea

Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19

Mechanistic Description of Dead and Dying Eukaryotic Cells

Dysregulation of Immune Response in Patients With Coronavirus

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients

Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain

Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Clinical predictors of mortality due to COVID -19 based on an analysis of data of 150 patients from Wuhan, China

A Well Infant With Coronavirus Disease 2019 With High Viral Load

Understanding the T cell immune response in SARS coronavirus infection

Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants

Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV

China puts 245 COVID-19 patients on convalescent plasma therapy

Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin

Chinese doctors "using plasma therapy" on COVID-19 patients, CNA

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Effects of chloroquine on viral infections: an old drug against today's diseases

Curb complement to cure COVID-19

Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous Nacetylcysteine | Elsevier Enhanced Reader

Treating COVID-19 with colchicine in community healthcare setting | Elsevier Enhanced Reader

History of the discovery of vitamin D and its active metabolites

The story of a vitamin for bone health that upgraded to hormone for systemic good health

Vitamin D: Metabolism

Vitamin D supplementation guidelines

Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects

Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)2vitamin D3: Genomic and non-genomic mechanisms

Vitamin D testing and treatment: a narrative review of current evidence

Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions

Vitamin D : Autoimmunity and Gender

Position Statement: Clinical Management of Vitamin D Deficiency in Adults

Vitamin D status as a synthetic biomarker of health status

Unveiling molecular associations of polymorphic variants of VDR gene (FokI, BsmI and ApaI) in multiple myeloma patients of Indian population

Blood Lead Levels in Occupationally Exposed Workers Involved in Battery Factories of Delhi-NCR Region: Effect on Vitamin D and Calcium Metabolism

Association of vitamin D receptor (VDR) gene polymorphism with blood lead levels in occupationally lead exposed male battery workers in Delhi -NCR region

Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials

Controversies in Vitamin D: Summary Statement From an International Conference

Respiratory Epithelial Cells Convert Inactive Vitamin D to Its Active Form: Potential Effects on Host Defense

Cutting Edge: Vitamin D-Mediated Human Antimicrobial Activity against Mycobacterium tuberculosis Is Dependent on the Induction of Cathelicidin

Janssens, 1,25-Dihydroxyvitamin D Modulates Antibacterial and Inflammatory Response in Human Cigarette Smoke-Exposed Macrophages

Vitamin D Deficiency and Acute Lung Injury

Does vitamin D status impact mortality from SARS-CoV-2 infection?

Vitamin D status has a linear association with seasonal infections and lung function in British adults

Epidemic influenza and vitamin D

Association Between Serum 25-Hydroxyvitamin D Level and Upper Respiratory Tract Infection in the Third National Health and Nutrition Examination Survey

Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren

Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19)

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID -19 infection

Self-Care for Common Colds: The Pivotal Role of Vitamin D, Vitamin C, Zinc, and Echinacea in Three Main Immune Interactive Clusters (Physical Barriers, Innate and Adaptive Immunity) Involved during an Episode of Common Colds-Practical Advice on Dosages and on the Time to Take These Nutrients/Botanicals in order to Prevent or Treat Common Colds

Mechanisms underlying the effect of vitamin D on the immune system

Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial

Mechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia

Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society

The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality

Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North-supports vitamin D as a factor determining severity. Authors' reply

PDF) Vitamin D deficiency: a factor in COVID-19, progression, severity and mortality? -An urgent call for research

Scientific Strabismus' or Two Related Pandemics: COVID-19 & Vitamin D Deficiency

Targeted 25-hydroxyvitamin D concentration measurements and vitamin D3 supplementation can have important patient and public health benefits

Vitamin D Supplementation Could Prevent and Treat Influenza, Coronavirus, and Pneumonia Infections

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

Latitude Dependence of the COVID-19 Mortality Rate-A Possible Relationship to Vitamin D Deficiency?

Vitamin D: modulator of the immune system

25-dihydroxyvitamin D3 receptors in human leukocytes

The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations

The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus

The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface

Modulation of the Immune Response to Respiratory Viruses by Vitamin D

Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D3

Role of Human β-Defensin-2 during Tumor Necrosis Factor-α/NF-κB-mediated Innate Antiviral Response against Human Respiratory Syncytial Virus

25-Dihydroxyvitamin D 3 -induced Monocyte Antimycobacterial Activity Is Regulated by Phosphatidylinositol 3-Kinase and Mediated by the NADPH-dependent Phagocyte Oxidase

Vitamin D, Vitamin D Receptor, and Macroautophagy in Inflammation and Infection

Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns

Suppressive Effect of 1α,25-Dihydroxyvitamin D 3 on Type I IFN-Mediated Monocyte Differentiation into Dendritic Cells: Impairment of Functional Activities and Chemotaxis

Immunosuppressive Actions of 1,25-Dihydroxyvitamin D3: Preferential Inhibition of Th1 Functions

25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4 + T Cells to Enhance the Development of Th2 Cells

Effects of Vitamin D on Airway Epithelial Cell Morphology and Rhinovirus Replication

Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?

Defective control of vitamin D receptor-mediated epithelial STAT1 signalling predisposes to severe respiratory syncytial virus bronchiolitis: Vitamin D receptor and RSV infection

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report, Infectious Diseases (except HIV/AIDS)

Short-Term Dexamethasone in Sars-CoV-2 Patients

Henry Ford COVID-19 Management Task Force, Early Short Course Corticosteroids in Hospitalized Patients with COVID-19

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Dexamethasone Enhances 1α,25-Dihydroxyvitamin D 3 Effects by Increasing Vitamin D Receptor Transcription

Glucocorticoid dexamethasone down-regulates basal and vitamin D3 induced cathelicidin expression in human monocytes and bronchial epithelial cell line

Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling

This review article did not receive grant funding from any funding agencies in the public, commercial, or not-for-profit sectors or professional writing assistance.J o u r n a l P r e -p r o o f